Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice
Experimental and Clinical Endocrinology & Diabetes · 01.09.2024 · 132 (09) · 507-514
DOI: 10.1055/a-2307-8036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.09.2024. Verfasst von Masahiro Takubo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes and Metabolism, Nihon University School of Medicine, 173-8610, Tokyo, Japan. Hauptthemen laut MEDLINE: Atherosclerosis, Sodium-Glucose Transporter 2 Inhibitors, Liraglutide, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Grants-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan, The Japan Association for Diabetes Education and Care.
Abstract (Originalsprache)
Background
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have beneficial effects on cardiovascular disease in addition to their glucose-lowering effects. In this study, the effects of these drugs, when used individually or in combination, on cardiovascular atherosclerotic lesion development were compared in diabetic ApoE-deficient (ApoE KO) hyperlipidemic mice.
Methods
ApoE-KO mice were treated with streptozotocin and nicotinamide, generating a type 2 diabetes model. The mice were randomly divided into four groups: vehicle-treated (untreated), liraglutide (LIRA), ipragliflozin (IPRA), and combination therapy (combo). These mice, as well as non-diabetic controls, were fed a high-fat diet. After 8 weeks of drug administration, the heart and aorta were removed and analyzed.
Results
Atherosclerotic lesions evaluated by oil red O (ORO) staining were significantly larger in the untreated group (13.4±0.8% of the total aortic area) than in the non-diabetic controls (4.4±0.5%, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Diabetes and Metabolism, Nihon University School of Medicine, 173-8610, Tokyo, Japan.
Förderung
- Grants-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan
- The Japan Association for Diabetes Education and Care
Zitieren
APA
Takubo, M., Watanabe, K., Saito, H., Kohno, G., & Ishihara, H. (2024). Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice. Experimental and Clinical Endocrinology & Diabetes, 132(09), 507-514. https://doi.org/10.1055/a-2307-8036
Vancouver
Takubo M, Watanabe K, Saito H, Kohno G, Ishihara H. Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice. Experimental and Clinical Endocrinology & Diabetes. 2024;132(09):507-514. doi:10.1055/a-2307-8036
BibTeX
@article{Takubo2024,
author = {Takubo, Masahiro and Watanabe, Kentaro and Saito, Hitoki and Kohno, Genta and Ishihara, Hisamitsu},
title = {Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2024},
volume = {132},
number = {09},
pages = {507--514},
doi = {10.1055/a-2307-8036}
}
EUVIMED